

LIFE SCIENCE TREND ANALYSIS

GERMANY | 2021



VENTURE VALUATION
GLOBAL VALUATION SERVICES



BIO DEUTSCHLAND

MAY 2021



ABOUT US



The following statistical information has been obtained from Biotechgate, a global, comprehensive life science database encompassing the biotechnology, pharmaceutical and medical device industries.

www.biotechgate.com



The German Biotech Database is a part of the global Biotechgate and is brought to you in partnership with BIO Deutschland, BIO.NRW, BioRN, and GTAI Germany Trade & Invest/HEALTH MADE IN GERMANY

www.germanbiotech.com





Biotechgate is owned and operated by Venture Valuation AG, a Zurich based company specializing in independent assessment and valuation of technology-driven companies in high growth industries, such as the life sciences (biotech, pharma, medtech), ICT, high-tech, nanotech, cleantech and renewable energy.

www.venturevaluation.com

OVERVIEW OF THE LIFE SCIENCE INDUSTRY



NUMBER OF COMPANIES BY SECTOR



For the definition of categories please visit www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html. Biotech Companies include the following categories: Biotechnology – Therapeutics and Diagnostics; Biotechnology – R&D; Biotechnology – Other. Percentage value is expressed as % of total number of companies. Information displayed may alter as new information is received continuously.

OVERVIEW OF BIOTECH COMPANIES


NUMBER OF COMPANIES BY SECTOR



For the definition of categories please visit www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html. Biotech Therapeutics category equals to Biotech Therapeutics and Diagnostics. Percentage value is expressed as % of total number of biotechnology companies. Information displayed may alter as new information is received continuously.

BIOTECH - THERAPEUTICS COMPANIES BY KEY ACTIVITIES

AS PERCENTAGE OF TOTAL NUMBER OF BIOTECH - THERAPEUTICS COMPANIES




For 1190 Biotech Therapeutics and Diagnostics companies there were 329 subsectors (key activity areas) assigned (one biotech company can be active in multiple areas). The graph displays subsectors as the percentage of the total number of Biotech – Therapeutics and Diagnostics subsectors with exclusion of the category Others. The company subsectors are regarded as the key activities of a company. For the definition of subsectors please visit www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html. Information displayed may alter as new information is received continuously.


BIOTECH ASSETS IN CLINICAL DEVELOPMENT

BY INDICATION AND DEVELOPMENT PHASE

BREAKDOWN BY INDICATION



BREAKDOWN BY DEVELOPMENT PHASE




Both graphs contain the number of assets of Biotech – Therapeutics and Diagnostics companies. Products in Discovery and Lead Optimization Phase are merged into Preclinical; development Phase I/II trials are merged into Phase II and Phase II/III trials are merged into Phase III category. Information displayed in the chart may alter as new information is received continuously

ASSETS AVAILABLE FOR OUT-LICENSING


NUMBER OF ASSETS

BY ASSET CLASS



■ Medical Devices ■ Diagnostics ■ Technologies ■ Therapeutics

THERAPEUTICS IN DEVELOPMENT BY DEVELOPMENT PHASE




■ Preclinical ■ Phase I ■ Phase II ■ Phase III

The graph titled Therapeutics in Development by Development Phase displays a subset of the asset class Therapeutics. Products in Discovery and Lead Optimization Phase are merged into Preclinical; Development Phase I/II trials are merged into Phase II and Phase II/III trials are merged into Phase III category.

OVERVIEW OF OWNERSHIP


PERCENTAGE OF TOTAL NUMBER OF COMPANIES BY OWNERSHIP AND SECTOR



For the definition of categories please visit www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html. Biotech T&D stands for Biotech Therapeutics and Diagnostics. Percentage value is expressed as % of total number of companies in the sector. Information displayed may alter as new information is received continuously.

COMPANY FOUNDATION TIMELINE

NUMBER OF LIFE SCIENCE COMPANIES FOUNDED BY YEAR | 2011-2019




The graph contains the number of privately owned or publicly listed (no subsidiaries) life science companies founded by year including Biotech - Therapeutic and Diagnostic, Biotech - R&D Services, Biotech - Others, Pharma, Medical Technology and Digital Health companies. **Companies founded in 2020 were excluded** since newly founded companies often remain under the radar until their first financing round. Information displayed in the chart may alter as new information is received continuously.


VENTURE FINANCING OF LIFE SCIENCE COMPANIES

PRIVATE EQUITY ROUNDS | 2019-2020

LIFE SCIENCE COMPANIES




BIOTECH COMPANIES



Life Science companies include Biotech - Therapeutic and Diagnostic, Biotech - R&D Services, Biotech - Others, Pharma, Medical Technology and Digital Health companies. Biotech companies are a subset of Life Science companies and include: Biotech - Therapeutic and Diagnostic, Biotech - R&D Services, Biotech - Others. Financing data only includes private equity rounds (excl. private placements in public companies). Data may alter as new information is continuously received and/or new tranches to existing financing rounds are added.

BIOTECH VENTURE FINANCING

PRIVATE EQUITY ROUNDS – 5 YEAR REPORT



Biotech companies are a subset of Life Science companies and include: Biotech - Therapeutic and Diagnostic, Biotech - R&D Services, Biotech – Others. Financing data only includes private equity rounds (excl. private placements in public companies) of biotech companies (incl. therapeutic and diagnostic, R&D services and others). Data may alter as new information is continuously received and/or new tranches to existing financing rounds are added.

MAJOR BIOTECH VENTURE FINANCING ROUNDS (2020)

TOP 5 PRIVATE EQUITY FINANCING ROUNDS | 2020

Company	Sector	Type of Round	USD M
CureVac AG	Biotech - Therapeutics	Other/unknown	\$631
CureVac AG	Biotech - Therapeutics	Other/unknown	\$171
CureVac AG	Biotech - Therapeutics	Other/unknown	\$126
ATAI Life Sciences AG	Biotech - Therapeutics	Series C	\$125
T-knife GmbH	Biotech - Therapeutics	Series A	\$78

The table shows the five biggest private equity financing rounds (excl. IPOs, research grants, loans) of private and independent biotech therapeutics and diagnostics companies in 2020. Information displayed in the table may alter as new information is continuously received and/or new tranches to existing financing rounds are added.

ABOUT BIOTECHGATE



Biotechgate is a **business development database** that contains nearly 60,000 high quality profiles of life science companies which include company description, contact information, product pipeline information, financing rounds and management details. Profiles are regularly updated by the companies themselves, as well as by an experienced database team, to ensure the accuracy and relevance of the data. Biotechgate contains also a database of 13,000 **licensing deals** and a **clinical trial database** containing over 600,000 records with registries from around the world.

To register for a free trial access or to learn more about the different subscription options, please visit www.biotechgate.com.

OUR PARTNERS



[HEALTH MADE IN GERMANY](#) is the export initiative for the German healthcare industry implemented by Germany Trade & Invest, the economic development agency of the Federal Republic of Germany, on behalf of the German Federal Ministry for Economic Affairs and Energy (BMWi).

HEALTH MADE IN GERMANY partnered with Venture Valuation/Biotechgate to create an [online company directory](#) that gives free access to more than 3500 profiles of companies active in the German healthcare market. The individual company profiles provide detailed information about each company's activities, product and services range, financial data and contact information. This allows to establish direct contact with potential partners in Germany.



OUR PARTNERS

BIO DEUTSCHLAND

As the sector association of the biotechnology industry, [BIO Deutschland](#) has set itself the objective of supporting and promoting the development of an innovative economic sector based on modern biosciences. BIO Deutschland is Germany's biotechnology sector representative at the BDI, the voice of the German Industry, and at the European association, EuropaBio, in Brussels. BIO Deutschland also works closely with other biotech organisations in Europe and the USA in order to lobby for the interests of the sector in an internationally coordinated way.

Venture Valuation/Biotechgate provides the [online directory](#) of BIO Deutschland member companies.

OUR PARTNERS



[BIO.NRW](#) is the official network for Biotechnology and Life Science in North Rhine-Westphalia (NRW), Germany's largest and economically most powerful federal state. Since 2009, BIO.NRW acts on behalf of the State Government of NRW and the office is run by the Juelich Research Center. BIO.NRW stimulates cooperation between companies, research institutes, and the state sector along value-added chains in the most important areas of Life Sciences – hereby setting a focus on the support of start-ups with regard to financing, internationalization and access to public funding, i.e. project consortia.

Thanks to the partnership with Venture Valuation, BIO.NRW provides [free database](#) of clear and comprehensive information about life science and biotechnology companies from North Rhine-Westphalia. The information includes company profiles, contact details and a summary of products, services and technologies.



OUR PARTNERS



[BioRN](#) is the science and industry cluster of the Rhine-MainNeckar region around Heidelberg, one of Germany's strongest biotech hubs. It is a non-profit network fostering health innovations and serving its members by creating a rich translational ecosystem as well as promoting, representing and connecting the regional innovation stakeholders. The vision of BioRN is to develop the region into a world leading life science cluster attracting international investments and top global talent.

BioRN has more than 100 institutional members, including the top academic and research institutions, 7 global pharmaceutical companies, a large range of small and medium-sized enterprises bolstering the life science ecosystem as well as local government organizations and interest groups.

Biotechgate/Venture Valuation provide the [Guide to the Region Rhine-Main-Neckar](#) available at the BioRN website.

TERMS OF USE

The Life Sciences Trend Analysis is based on data entered in the Biotechgate Database available at www.biotechgate.com. The statistics and graphs in this presentation are based on figures and information entered in this database and we do not guarantee any accuracy hereof.

The use of the figures and graphs provided in this report is free of charge for any presentations as long as www.biotechgate.com is clearly cited as the source. For all other uses please contact us for terms and conditions.



BIOTECHGATE

c/o Venture Valuation VV AG

Kasernenstrasse 11

8004 Zurich

SWITZERLAND



+41 (43) 321 86 60



www.venturevaluation.com

